Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria

E. Matutes, D. Oscier, C. Montalban, F. Berger, E. Callet-Bauchu, A. Dogan, P. Felman, V. Franco, E. Iannitto, M. Mollejo, T. Papadaki, Ellen McPhail, A. Salar, F. Solé, K. Stamatopoulos, C. Thieblemont, A. Traverse-Glehen, A. Wotherspoon, B. Coiffier, M. A. Piris

Research output: Contribution to journalArticle

162 Citations (Scopus)

Abstract

Since the initial description of splenic marginal zone lymphoma (SMZL) in 1992, an increasing number of publications have dealt with multiple aspects of SMZL diagnosis, molecular pathogenesis and treatment. This process has identified multiple inconsistencies in the diagnostic criteria and lack of clear guidelines for the staging and treatment. The authors of this review have held several meetings and exchanged series of cases with the objective of agreeing on the main diagnostic, staging and therapeutic guidelines for patients with this condition. Specific working groups were created for diagnostic criteria, immunophenotype, staging and treatment. As results of this work, guidelines are proposed for diagnosis, differential diagnosis, staging, prognostic factors, treatment and response criteria. The guidelines proposed here are intended to contribute to the standardization of the diagnosis and treatment of these patients, and should facilitate the future development of clinical trials that could define more precisely predictive markers for histological progression or lack of response, and evaluate new drugs or treatments.

Original languageEnglish (US)
Pages (from-to)487-495
Number of pages9
JournalLeukemia
Volume22
Issue number3
DOIs
StatePublished - Mar 2008

Fingerprint

Lymphoma
Guidelines
Therapeutics
Publications
Differential Diagnosis
Clinical Trials
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Matutes, E., Oscier, D., Montalban, C., Berger, F., Callet-Bauchu, E., Dogan, A., ... Piris, M. A. (2008). Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia, 22(3), 487-495. https://doi.org/10.1038/sj.leu.2405068

Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. / Matutes, E.; Oscier, D.; Montalban, C.; Berger, F.; Callet-Bauchu, E.; Dogan, A.; Felman, P.; Franco, V.; Iannitto, E.; Mollejo, M.; Papadaki, T.; McPhail, Ellen; Salar, A.; Solé, F.; Stamatopoulos, K.; Thieblemont, C.; Traverse-Glehen, A.; Wotherspoon, A.; Coiffier, B.; Piris, M. A.

In: Leukemia, Vol. 22, No. 3, 03.2008, p. 487-495.

Research output: Contribution to journalArticle

Matutes, E, Oscier, D, Montalban, C, Berger, F, Callet-Bauchu, E, Dogan, A, Felman, P, Franco, V, Iannitto, E, Mollejo, M, Papadaki, T, McPhail, E, Salar, A, Solé, F, Stamatopoulos, K, Thieblemont, C, Traverse-Glehen, A, Wotherspoon, A, Coiffier, B & Piris, MA 2008, 'Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria', Leukemia, vol. 22, no. 3, pp. 487-495. https://doi.org/10.1038/sj.leu.2405068
Matutes E, Oscier D, Montalban C, Berger F, Callet-Bauchu E, Dogan A et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia. 2008 Mar;22(3):487-495. https://doi.org/10.1038/sj.leu.2405068
Matutes, E. ; Oscier, D. ; Montalban, C. ; Berger, F. ; Callet-Bauchu, E. ; Dogan, A. ; Felman, P. ; Franco, V. ; Iannitto, E. ; Mollejo, M. ; Papadaki, T. ; McPhail, Ellen ; Salar, A. ; Solé, F. ; Stamatopoulos, K. ; Thieblemont, C. ; Traverse-Glehen, A. ; Wotherspoon, A. ; Coiffier, B. ; Piris, M. A. / Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. In: Leukemia. 2008 ; Vol. 22, No. 3. pp. 487-495.
@article{e89a43276b6e453bbe7790de7769eaeb,
title = "Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria",
abstract = "Since the initial description of splenic marginal zone lymphoma (SMZL) in 1992, an increasing number of publications have dealt with multiple aspects of SMZL diagnosis, molecular pathogenesis and treatment. This process has identified multiple inconsistencies in the diagnostic criteria and lack of clear guidelines for the staging and treatment. The authors of this review have held several meetings and exchanged series of cases with the objective of agreeing on the main diagnostic, staging and therapeutic guidelines for patients with this condition. Specific working groups were created for diagnostic criteria, immunophenotype, staging and treatment. As results of this work, guidelines are proposed for diagnosis, differential diagnosis, staging, prognostic factors, treatment and response criteria. The guidelines proposed here are intended to contribute to the standardization of the diagnosis and treatment of these patients, and should facilitate the future development of clinical trials that could define more precisely predictive markers for histological progression or lack of response, and evaluate new drugs or treatments.",
author = "E. Matutes and D. Oscier and C. Montalban and F. Berger and E. Callet-Bauchu and A. Dogan and P. Felman and V. Franco and E. Iannitto and M. Mollejo and T. Papadaki and Ellen McPhail and A. Salar and F. Sol{\'e} and K. Stamatopoulos and C. Thieblemont and A. Traverse-Glehen and A. Wotherspoon and B. Coiffier and Piris, {M. A.}",
year = "2008",
month = "3",
doi = "10.1038/sj.leu.2405068",
language = "English (US)",
volume = "22",
pages = "487--495",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria

AU - Matutes, E.

AU - Oscier, D.

AU - Montalban, C.

AU - Berger, F.

AU - Callet-Bauchu, E.

AU - Dogan, A.

AU - Felman, P.

AU - Franco, V.

AU - Iannitto, E.

AU - Mollejo, M.

AU - Papadaki, T.

AU - McPhail, Ellen

AU - Salar, A.

AU - Solé, F.

AU - Stamatopoulos, K.

AU - Thieblemont, C.

AU - Traverse-Glehen, A.

AU - Wotherspoon, A.

AU - Coiffier, B.

AU - Piris, M. A.

PY - 2008/3

Y1 - 2008/3

N2 - Since the initial description of splenic marginal zone lymphoma (SMZL) in 1992, an increasing number of publications have dealt with multiple aspects of SMZL diagnosis, molecular pathogenesis and treatment. This process has identified multiple inconsistencies in the diagnostic criteria and lack of clear guidelines for the staging and treatment. The authors of this review have held several meetings and exchanged series of cases with the objective of agreeing on the main diagnostic, staging and therapeutic guidelines for patients with this condition. Specific working groups were created for diagnostic criteria, immunophenotype, staging and treatment. As results of this work, guidelines are proposed for diagnosis, differential diagnosis, staging, prognostic factors, treatment and response criteria. The guidelines proposed here are intended to contribute to the standardization of the diagnosis and treatment of these patients, and should facilitate the future development of clinical trials that could define more precisely predictive markers for histological progression or lack of response, and evaluate new drugs or treatments.

AB - Since the initial description of splenic marginal zone lymphoma (SMZL) in 1992, an increasing number of publications have dealt with multiple aspects of SMZL diagnosis, molecular pathogenesis and treatment. This process has identified multiple inconsistencies in the diagnostic criteria and lack of clear guidelines for the staging and treatment. The authors of this review have held several meetings and exchanged series of cases with the objective of agreeing on the main diagnostic, staging and therapeutic guidelines for patients with this condition. Specific working groups were created for diagnostic criteria, immunophenotype, staging and treatment. As results of this work, guidelines are proposed for diagnosis, differential diagnosis, staging, prognostic factors, treatment and response criteria. The guidelines proposed here are intended to contribute to the standardization of the diagnosis and treatment of these patients, and should facilitate the future development of clinical trials that could define more precisely predictive markers for histological progression or lack of response, and evaluate new drugs or treatments.

UR - http://www.scopus.com/inward/record.url?scp=40749143143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40749143143&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2405068

DO - 10.1038/sj.leu.2405068

M3 - Article

C2 - 18094718

AN - SCOPUS:40749143143

VL - 22

SP - 487

EP - 495

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 3

ER -